Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment. By adding a newer, targeted therapy aimed at the underlying IDH ...

The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...

Two years ago, as she was walking into yoga class, Maddy momentarily found herself unable to speak. At first, she thought it was due to anxiety about school, but when it kept happening, and the right ...

Assessment of personhood indicators for instrument development for persons with primary brain tumors. Background: Better understanding of underlying molecular mechanisms and alterations have led to ...